XML 35 R20.htm IDEA: XBRL DOCUMENT
v3.23.3

Note 13 - Income Taxes | 12 Months Ended
--- | ---
Sep. 30, 2023
Notes to Financial Statements |
Income Tax Disclosure [Text Block] | 13. INCOME TAXES Income taxes consisted of the following:
|  | Years ended September 30, |
|  | 2023 |  |  | 2022 |
Current tax provision |  |  |  |  |  |  |  |
Federal |  | $ | - |  |  | $ | - |
State |  |  | 16 |  |  |  | 3 |
Foreign |  |  | 11 |  |  |  | 70 |
Total current tax provision |  |  | 27 |  |  |  | 73 |
Deferred provision |  |  |  |  |  |  |  |
Federal |  |  | 6,266 |  |  |  | 568 |
State |  |  | 1,107 |  |  |  | 100 |
Total deferred provision |  |  | 7,373 |  |  |  | 668 |
Provision for income taxes |  | $ | 7,400 |  |  | $ | 741 |
A reconciliation of income taxes at the federal statutory rate of 21% to the effective tax rate was as follows:
|  | Years ended September 30, |
|  | 2023 |  |  | 2022 |
Income taxes computed at the federal statutory rate |  | $ | (2,309 | ) |  | $ | (3,314 | )
Change in valuation allowance |  |  | 10,376 |  |  |  | 1,065 |
Nondeductible compensation, interest expense and other |  |  | 232 |  |  |  | 4,101 |
State income taxes, net of federal tax benefit |  |  | (605 | ) |  |  | (859 | )
Change in R&D credit carryover |  |  | (433 | ) |  |  | (186 | )
Stock options and other prior year true-ups |  |  | 111 |  |  |  | 25 |
Foreign rate differential & foreign taxes |  |  | 28 |  |  |  | (1 | )
State business credit utilization |  |  | - |  |  |  | (90 | )
|  | $ | 7,400 |  |  | $ | 741 |
The types of temporary differences between the tax basis of assets and liabilities and their approximate tax effects that give rise to a significant portion of the net deferred tax asset as of September 30, 2023 and 2022 were as follows:
|  | September 30, |
|  | 2023 |  |  | 2022 |
Deferred tax assets |  |  |  |  |  |  |  |
Net operating loss carryforwards |  | $ | 10,665 |  |  | $ | 10,054 |
Research and development credit |  |  | 4,929 |  |  |  | 4,712 |
Share-based compensation |  |  | 650 |  |  |  | 688 |
Patents |  |  | 2,203 |  |  |  | 2,331 |
Accruals and other |  |  | 2,071 |  |  |  | 2,245 |
Capitalized R&E expenses |  |  | 1,916 |  |  |  | - |
Allowances |  |  | 237 |  |  |  | 280 |
Gross deferred tax assets |  |  | 22,671 |  |  |  | 20,310 |
Deferred tax liabilities |  |  |  |  |  |  |  |
Equipment |  |  | (274 | ) |  |  | (313 | )
Operating ROU assets |  |  | (907 | ) |  |  | (1,066 | )
Acquired intangible assets |  |  | (1,736 | ) |  |  | (2,180 | )
Gross deferred tax liabilities |  |  | (2,917 | ) |  |  | (3,559 | )
Less valuation allowance |  |  | (19,754 | ) |  |  | (9,378 | )
Net deferred tax assets and liabilities |  | $ | - |  |  | $ | 7,373 |
As of September 30, 2023, the Company had net deferred tax assets and liabilities of approximately $0 due to the establishment of a full valuation allowance against its net deferred tax assets. The deferred tax assets are primarily comprised of federal and state NOL carryforwards and federal and state research and development (“R&D”) tax credit carryforwards offset by valuation allowance. As of September 30, 2023, the Company had federal NOL carryforwards of approximately $32,390, which expire from tax years September 30, 2024 through 2037, except for $1,526 which have an indefinite carryforward period. The Company also has an estimated $2,844 and $306 of federal and California R&D tax credits, respectively, as of September 30, 2023, where a portion of federal R&D tax credits will begin to expire in 2024. The California R&D tax credits do not expire. The Company reviews its ability to realize its deferred tax assets on a quarterly basis. In doing so, management considers historical and projected taxable income of the Company, along with any tax planning strategies and any other positive or negative evidence. Realization is dependent on generating sufficient taxable income prior to the expiration of the loss carryforwards and other deferred assets. As of September 30, 2023, the Company does not believe that it is more likely than not that its deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying balance sheet. As of September 30, 2023, the Company had no unrecognized tax benefits. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, the annual use of the Company’s net operating loss and R&D tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Due to the existence of the valuation allowance, any permanent limitations on the use of the Company’s net operating loss and research and development credit carryforwards will not impact the Company’s effective tax rate. The Company is subject to taxation in the U.S. and various foreign jurisdictions. The Company's U.S. federal tax returns since September 30, 2004 are subject to examination by the Internal Revenue Service due to the generation of U.S. federal NOL and credit carryforwards. The Company's U.S. state returns are generally subject to examination for four years after the filing date. The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research & experimental ("R&E") costs under IRC Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&E costs that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically, costs for U.S. based R&E activities must be amortized over five years and costs for foreign R&E activities must be amortized over 15 years; both using a mid-year convention. The Company has incorporated the impact of this new tax legislation into its 2022 consolidated financial statements and established a $1,916 deferred tax asset for the remaining amortizable tax basis in its 2022 R&E costs in the table of deferred taxes above. The impact on the Company’s consolidated financial statements was immaterial given the full valuation allowance against the Company’s U.S. net deferred tax assets.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration